Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Zamboni

Showing results (151-160 of 180) with videos related to

Pageof 18
Sort By:
European Journal of Clinical Pharmacology|August 31, 2013
Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumorsHuali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
International Journal of Pharmaceutics|May 6, 2017
Pharmacokinetic and screening studies of the interaction between mononuclear phagocyte system and nanoparticle formulations and colloid forming drugsAndrew T Lucas, Leah B Herity, Zack A Kornblum, et al.
Plos One|May 8, 2013
Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancerCarey K Anders, Barbara Adamo, Olga Karginova, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|June 21, 2015
Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancerGina Song, Teresa K Tarrant, Taylor F White, et al.
Investigational New Drugs|March 1, 2006
Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypesWilliam C Zamboni, Ramesh K Ramanathan, Howard L McLeod, et al.
Cancer Chemotherapy and Pharmacology|December 16, 2003
Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanomaWilliam C Zamboni, Anne C Gervais, Merrill J Egorin, et al.
ACS Nano|November 24, 2015
Tumor Presence Induces Global Immune Changes and Enhances Nanoparticle ClearanceMarc P Kai, Hailey E Brighton, Catherine A Fromen, et al.
Therapeutic Advances in Medical Oncology|November 4, 2021
Minibeam radiation therapy enhanced tumor delivery of PEGylated liposomal doxorubicin in a triple-negative breast cancer mouse modelLauren S L Price, Judith N Rivera, Andrew J Madden, et al.
Clinical Breast Cancer|November 21, 2017
A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast CancerAutumn J McRee, Paul K Marcom, Dominic T Moore, et al.
International Journal of Nanomedicine|February 25, 2015
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumorsHuali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
Pageof 18

Showing results (151-160 of 180) with videos related to

Sort By:
Pageof 18
European Journal of Clinical Pharmacology|August 31, 2013
Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumorsHuali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
International Journal of Pharmaceutics|May 6, 2017
Pharmacokinetic and screening studies of the interaction between mononuclear phagocyte system and nanoparticle formulations and colloid forming drugsAndrew T Lucas, Leah B Herity, Zack A Kornblum, et al.
Plos One|May 8, 2013
Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancerCarey K Anders, Barbara Adamo, Olga Karginova, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|June 21, 2015
Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancerGina Song, Teresa K Tarrant, Taylor F White, et al.
Investigational New Drugs|March 1, 2006
Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypesWilliam C Zamboni, Ramesh K Ramanathan, Howard L McLeod, et al.
Cancer Chemotherapy and Pharmacology|December 16, 2003
Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanomaWilliam C Zamboni, Anne C Gervais, Merrill J Egorin, et al.
ACS Nano|November 24, 2015
Tumor Presence Induces Global Immune Changes and Enhances Nanoparticle ClearanceMarc P Kai, Hailey E Brighton, Catherine A Fromen, et al.
Therapeutic Advances in Medical Oncology|November 4, 2021
Minibeam radiation therapy enhanced tumor delivery of PEGylated liposomal doxorubicin in a triple-negative breast cancer mouse modelLauren S L Price, Judith N Rivera, Andrew J Madden, et al.
Clinical Breast Cancer|November 21, 2017
A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast CancerAutumn J McRee, Paul K Marcom, Dominic T Moore, et al.
International Journal of Nanomedicine|February 25, 2015
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumorsHuali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
Pageof 18